Staphylococcus aureus CcpA affects virulence determinant production and antibiotic resistance.
Carbon catabolite protein A (CcpA) is known to function as a major regulator of gene expression in different gram-positive organisms. Deletion of the ccpA homologue (saCOL1786) in Staphylococcus aureus was found to affect growth, glucose metabolization, and transcription of selected virulence determinants. In liquid culture, deletion of CcpA decreased the growth rate and yield; however, the effect was only transient during the exponential-growth phase as long as glucose was present in the medium. Depletion of glucose and production of lactate was delayed, while the level of excretion of acetate was less affected and was even higher in the mutant culture. On solid medium, in contrast, growth of the DeltaccpA mutant resulted in smaller colonies containing a lower number of CFU per colony. Deletion of CcpA had an effect on the expression of important virulence factors of S. aureus by down-regulating RNAIII, the effector molecule of the agr locus, and altering the transcription patterns of hla, encoding alpha-hemolysin, and spa, encoding protein A. CcpA inactivation markedly reduced the oxacillin resistance levels in the highly methicillin-resistant S. aureus strain COLn and the teicoplanin resistance level in a glycopeptide-intermediate-resistant S. aureus strain. The presence of CcpA in the capsular polysaccharide serotype 5 (CP5)-producing strain Newman abolished capsule formation and decreased cap operon transcription in the presence of glucose. The staphylococcal CcpA thus not only is involved in the regulation of carbon metabolism but seems to function as a modulator of virulence gene expression as well.
Department of Medical Microbiology, University of Zürich, Gloriastr. 32, CH-8006 Zürich, Switzerland, and Institute for Medical Microbiology and Hygiene, University Hospital Tübingen, Germany.
Kati
K
Seidl
Martin
M
Stucki
Martin
M
Ruegg
Christiane
C
Goerke
Christiane
C
Wolz
Llinos
L
Harris
Brigitte
B
Berger-Bächi
Markus
M
Bischoff
D016667:Bacterial Capsules / Q000096:biosynthesis; D001426:Bacterial Proteins / Q000502:physiology*; D050260:Carbohydrate Metabolism; D004268:DNA-Binding Proteins / Q000502:physiology*; D024881:Drug Resistance, Bacterial; D005947:Glucose / Q000494:pharmacology; D006863:Hydrogen-Ion Concentration; D016372:RNA, Antisense / Q000235:genetics; D012329:RNA, Bacterial / Q000235:genetics; D012097:Repressor Proteins / Q000502:physiology*; D020218:Response Elements / Q000502:physiology; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000254:growth & development / Q000472:pathogenicity*; D014774:Virulence; D037521:Virulence Factors / Q000096:biosynthesis*
D001426:Bacterial Proteins; D004268:DNA-Binding Proteins; D016372:RNA, Antisense; D012329:RNA, Bacterial; C096035:RNAIII, Staphylococcus aureus; D012097:Repressor Proteins; D037521:Virulence Factors; C069286:catabolite control proteins, bacteria; D005947:Glucose